Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT03300557
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT03291886
- Locations
- 🇯🇵
Tsukuba University Hospital, Tsukuba, Ibaraki, Japan
🇯🇵National Cancer Center Hospital, Chuo, Tokyo, Japan
🇯🇵Toranomon Hospital, Minato, Tokyo, Japan
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT03280563
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03238703
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 532
- Registration Number
- NCT03220178
- Locations
- 🇩🇪
University Hospital Mainz, Mainz, Germany
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 37
- Registration Number
- NCT03219476
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT03179904
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 235
- Registration Number
- NCT03176238
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT02983604
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Stanford, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.